VRNA
Verona Pharma plc Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website veronapharma.com
- Employees(FY) 35
- ISIN US9250501064
Performance
-5.71%
1W
-9.84%
1M
-12.7%
3M
+8.55%
6M
-25.3%
YTD
-36.62%
1Y
Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Investment Analysis Report: VRNA
Overview
In this investment analysis report, we will delve into the financial statements of VRNA, a pharmaceutical company in the Health Technology sector. We will analyze the company's valuation, financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, capital expendit...
Technical Analysis of VRNA 2024-05-03
Overview:
In analyzing the technical indicators for VRNA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-09 11:38
- 2024-05-09 11:04
Verona Pharma Shares Decline After Q1 Loss Widens(MT Newswires)
- 2024-05-09 07:15
- 2024-05-09 07:00
- 2024-05-08 19:15
- 2024-05-08 19:00
- 2024-05-08 01:22
- 2024-05-02 02:00
- 2024-05-01 14:00
- 2024-04-25 02:00
- 2024-04-24 14:00
- 2024-03-04 02:00
Andrew Fisher Joins Verona Pharma as General Counsel(GlobeNewswire)
- 2024-03-03 13:00
Andrew Fisher Joins Verona Pharma as General Counsel(Globenewswire)
- 2024-03-01 09:03
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript(Insider Monkey)
- 2024-03-01 08:45
- 2024-02-29 20:03
- 2024-02-29 06:36
- 2024-02-29 02:00
- 2024-02-28 13:00
- 2024-02-25 07:48
When Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?(Simply Wall St.)
- 2024-02-15 02:00
- 2024-02-14 13:00
- 2024-02-01 02:00
- 2024-01-31 13:00
- 2024-01-15 08:11
- 2024-01-03 02:00
- 2024-01-02 13:00
- 2024-01-02 13:00
- 2024-01-02 02:00
- 2023-12-30 06:50
3 Stocks That Could Be Monster Winners in 2024(Motley Fool)
Page 1 of 5
previousnext